Steffen Koschmieder

11.0k total citations
222 papers, 5.2k citations indexed

About

Steffen Koschmieder is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Steffen Koschmieder has authored 222 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 149 papers in Hematology, 122 papers in Genetics and 95 papers in Molecular Biology. Recurrent topics in Steffen Koschmieder's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (91 papers), Acute Myeloid Leukemia Research (86 papers) and Chronic Myeloid Leukemia Treatments (75 papers). Steffen Koschmieder is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (91 papers), Acute Myeloid Leukemia Research (86 papers) and Chronic Myeloid Leukemia Treatments (75 papers). Steffen Koschmieder collaborates with scholars based in Germany, United States and United Kingdom. Steffen Koschmieder's co-authors include Carsten Müller‐Tidow, Daniel G. Tenen, Wolfgang E. Berdel, Tim H. Brümmendorf, Mirle Schemionek, Nicolas Chatain, Hubert Serve, Etmar Bulk, Antje Hascher and Alessandro Marra and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Steffen Koschmieder

209 papers receiving 5.1k citations

Peers

Countries citing papers authored by Steffen Koschmieder

Since Specialization

Citations

This map shows the geographic impact of Steffen Koschmieder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steffen Koschmieder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steffen Koschmieder more than expected).

Fields of papers citing papers by Steffen Koschmieder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steffen Koschmieder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steffen Koschmieder. The network helps show where Steffen Koschmieder may publish in the future.

Co-authorship network of co-authors of Steffen Koschmieder

This figure shows the co-authorship network connecting the top 25 collaborators of Steffen Koschmieder. A scholar is included among the top collaborators of Steffen Koschmieder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steffen Koschmieder. Steffen Koschmieder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) - practical approaches of a German expert panel discussion in 2024 2025 ·Annals of Hematology ·Martin Grießhammer, Haifa Kathrin Al‐Ali, Jan‐Niklas Eckardt, Michael Fiegl, Joachim R. Göthert, Kathleen Jentsch‐Ullrich, Steffen Koschmieder, Hans Michael Kvasnicka, Andreas Reiter, Burkhard Schmidt, Florian H. Heidel	1
2	Impact of hemoglobin improvement with momelotinib on survival in patients with myelofibrosis and anemia: Post hoc analyses of the simplify-1 and momentum trials 2025 ·Blood ·Francesca Palandri, Casey L. O’Connell, Pankit Vachhani, Donal P. McLornan, Steffen Koschmieder, Juan Carlos Hernández‐Boluda, Catherine Ellis, (unknown), Shiyuan Zhang, (unknown), (unknown), (unknown)	0
3	NLRP3-induced systemic inflammation controls the development of JAK2V617F mutant myeloproliferative neoplasms 2025 ·Nature Communications ·(unknown), (unknown), (unknown), (unknown), (unknown), Tim H. Brümmendorf, Steffen Koschmieder, Martin Grießhammer, Ines Gütgemann, (unknown), T Fischer, Peter Brossart, (unknown), Eicke Latz, Dominik Wolf‎, Lino L. Teichmann	0
4	ZIP10 as a potential therapeutic target in acute myeloid leukaemia 2025 ·British Journal of Haematology ·Benjamin Rolles, Nicolas Chatain, (unknown), Margherita Vieri, (unknown), (unknown), (unknown), (unknown), (unknown), Kyle A. Romine, KM Taylor, Jens Bertram, Edgar Jost, Steffen Koschmieder, Fabian Beier, Maximilian Stahl, Tim H. Brümmendorf, Lothar Rink, Inga Weßels	1
5	Cell Adhesion and Local Cytokine Control on Protein‐Functionalized PNIPAM‐co‐AAc Hydrogel Microcarriers 2024 ·Small ·Sebastian Rauer, (unknown), (unknown), Marcelo A. S. Toledo, G. Fischer, (unknown), (unknown), Steffen Koschmieder, Matthias Weßling, John Linkhorst	3
6	Myelofibrosis: Current unmet needs, emerging treatments, and future perspectives 2024 ·Cancer ·Claire Harrison, Jean‐Jacques Kiladjian, Steffen Koschmieder, Francesco Passamonti	2
7	Bone marrow biopsy in geriatric patients above the age of 85 years: invaluable or unnecessary? A retrospective analysis 2024 ·Annals of Hematology ·(unknown), Edgar Jost, Jens Panse, (unknown), (unknown), Danny Jonigk, (unknown), (unknown), (unknown), Tim H. Brümmendorf, Steffen Koschmieder, Susanne Isfort	1
8	Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN) 2023 ·Leukemia ·Frank Stegelmann, Lino L. Teichmann, Florian H. Heidel, (unknown), Thomas Ernst, Sebastian Kreil, Andreas Reiter, (unknown), Stefanie Schauer, (unknown), (unknown), Susanne Isfort, Hartmut Döhner, Tim H. Brümmendorf, Martin Grießhammer, Konstanze Döhner, Steffen Koschmieder	5
9	Targeted DNA Methylation Analysis Facilitates Leukocyte Counts in Dried Blood Samples 2023 ·Clinical Chemistry ·(unknown), Tiago Maié, (unknown), (unknown), Deepika Puri, (unknown), Jan Kramer, Lothar Rink, Steffen Koschmieder, Ivan G. Costa, Wolfgang Wagner	6
10	Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial 2023 ·Annals of Hematology ·Steffen Koschmieder, Susanne Isfort, Clemens Schulte, Lutz Jacobasch, Thomas Geer, Marcel Reiser, Michael Koenigsmann, Bernhard Heinrich, (unknown), (unknown), Hans Tesch, (unknown), (unknown), (unknown), Heike L. Pahl	6
11	Toward Clinical Application of Leukocyte Counts Based on Targeted DNA Methylation Analysis 2022 ·Clinical Chemistry ·Stephanie Sontag, (unknown), (unknown), (unknown), (unknown), Thomas Look, (unknown), Birgit Plümäkers, (unknown), (unknown), Thomas Kraus, Jan Kramer, Lothar Rink, Steffen Koschmieder, Wolfgang Wagner	12
12	Kindlin-3 loss curbs chronic myeloid leukemia in mice by mobilizing leukemic stem cells from protective bone marrow niches 2020 ·Proceedings of the National Academy of Sciences ·Peter W. Krenn, Steffen Koschmieder, Reinhard Fässler	17
13	Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm 2020 ·Annals of Hematology ·(unknown), Peter Boor, Andreas Buneß, Rebekka K. Schneider, Lino L. Teichmann, (unknown), Gábor Horváth, Steffen Koschmieder, Ines Gütgemann	9
14	Potential Technologies Review: A hybrid information retrieval framework to accelerate demand‐pull innovation in biomedical engineering 2019 ·Research Synthesis Methods ·Tom Schmitz, (unknown), Steffen Koschmieder, Thomas Schmitz‐Rode, (unknown)	2
15	Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients 2018 ·Cancer Research ·Liye He, Jing Tang, Emma Andersson, Sanna Timonen, Steffen Koschmieder, Krister Wennerberg, Satu Mustjoki, Tero Aittokallio	55
16	Leukocyte Counts Based on DNA Methylation at Individual Cytosines 2017 ·Clinical Chemistry ·Joana Frobel, (unknown), Michael Lenz, Peter Uciechowski, Yang Han, (unknown), Klaus Strathmann, Susanne Isfort, Jens Panse, André Esser, (unknown), (unknown), Thomas Kraus, Lothar Rink, Steffen Koschmieder, Wolfgang Wagner	18
17	The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey 2017 ·Annals of Hematology ·Claire Harrison, Steffen Koschmieder, Lynda Foltz, Paola Guglielmelli, (unknown), Michael Koehler, (unknown), Norio Komatsu, (unknown), (unknown), Julian Perez Ronco, Gavin Taylor‐Stokes, John Waller, Ruben A. Mesa	80
18	JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms 2015 ·Cancer Research ·Kathrin Schönberg, Janna Rudolph, (unknown), Sowmya Parampalli Yajnanarayana, Isabelle Cornez, Maryam Hejazi, Angela R. Manser, Markus Uhrberg, Walter Verbeek, Steffen Koschmieder, Tim H. Brümmendorf, Peter Brossart, Annkristin Heine, Dominik Wolf‎	123
19	Inhibitor of Cyclin-dependent Kinase (CDK) Interacting with Cyclin A1 (INCA1) Regulates Proliferation and Is Repressed by Oncogenic Signaling 2011 ·Journal of Biological Chemistry ·Nicole Bäumer, Lara Tickenbrock, Petra Tschanter, (unknown), Sven Diederichs, Sebastian Bäumer, Boris V. Skryabin, Feng Zhang, Shuchi Agrawal‐Singh, Gabriele Köhler, Wolfgang E. Berdel, Hubert Serve, Steffen Koschmieder, Carsten Müller‐Tidow	19
20	DNA Methylation of Tumor Suppressor Genes in Clinical Remission Predicts the Relapse Risk in Acute Myeloid Leukemia 2007 ·Cancer Research ·Shuchi Agrawal, Matthias Unterberg, Steffen Koschmieder, Udo zur Stadt, Uta Brunnberg, Walter Verbeek, Thomas Büchner, Wolfgang E. Berdel, Hubert Serve, Carsten Müller‐Tidow	81

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact